Crossmark

Biologic Disease-modifying Antirheumatic Drug Attributes in the First Lines of Treatment of Rheumatoid Arthritis. 2015 ACORDAR Project

Crossref DOI link: https://doi.org/10.1016/j.reumae.2016.10.005

Published Print: 2018-03

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Muñoz-Fernández, Santiago

Bustabad Reyes, María Sagrario

Calvo Alén, Jaime

Castaño Sánchez, Manuel

Chamizo Carmona, Eugenio

Corominas, Héctor

Fernández-Llanio Comella, Nagore

Hidalgo Calleja, María Cristina

Pérez Venegas, José Javier

Rodríguez Heredia, José Manuel

Romero Yuste, Susana María

Ruiz-Esquide Torino, Virginia
Funding

Funding for this research was provided by:

Bristol-Myers Squibb
License Information

Text and Data Mining valid from 2018-03-01
More Information

This article is maintained by: Elsevier

Article Title: Biologic Disease-modifying Antirheumatic Drug Attributes in the First Lines of Treatment of Rheumatoid Arthritis. 2015 ACORDAR Project

Journal Title: Reumatología Clínica (English Edition)

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.reumae.2016.10.005

CrossRef DOI link to the associated document: https://doi.org/10.1016/j.reuma.2016.10.001

Content Type: article

Copyright: © 2016 Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología. All rights reserved.